Cardio Diagnostics Reports Q1 Loss, Raises $3.7M via ATM, Discloses Internal Control Weakness
CDIO sits 60% above its 52-week low of $0.97.
Summary
Cardio Diagnostics reported increased Q1 losses and minimal revenue, relying on a highly dilutive ATM offering for cash. The company also disclosed a material weakness in internal controls, raising significant financial and operational concerns.
Key Events · Financing and Capital Events · CDIO
-
Increased Net Loss and Minimal Revenue
The company reported a net loss of $(1,788,158) for Q1 2026, an increase from $(1,635,064) in Q1 2025, on extremely low revenue of $2,680.
-
Significant Dilutive Financing
Cardio Diagnostics raised $3,693,470 in net proceeds by selling 1,133,418 common shares through its At-The-Market (ATM) program during Q1 2026. This represents approximately 62% dilution relative to shares outstanding at the end of the prior quarter.
-
Substantial Remaining ATM Capacity
The company has approximately $5.3 million remaining under its ATM program, which, if fully utilized at current prices, could issue over 3.4 million shares, representing more than 115% potential dilution to current shareholders.
-
Material Weakness in Internal Controls
Management identified a material weakness in internal control over financial reporting due to inadequate segregation of duties within the financial reporting process, increasing the risk of errors or unauthorized transactions.
Analysis · CDIO · Life Sciences
Cardio Diagnostics continues to face significant financial challenges, reporting increased net losses and minimal revenue. The company is heavily reliant on its At-The-Market (ATM) offering for liquidity, having raised $3.7 million in Q1 2026, which represents a substantial portion of its small market capitalization. The remaining ATM capacity is even larger than the current market cap, indicating potential for extreme future dilution. Additionally, management identified a material weakness in internal controls over financial reporting, a serious compliance concern. While the rescission of the FDA's LDT rule is a positive regulatory development for the business model, it does not offset the immediate financial distress and operational risks.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDIO was trading at $1.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $0.97 to $7.91. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.